Appili Therapeutics
@appili.bsky.social
Dedicated to identifying, acquiring and advancing novel therapeutics for #InfectiousDiseases
$APLI $APLIF
$APLI $APLIF
Millions suffer from NTDs with limited treatment options. The FDA PRV program incentivizes biotechs to develop treatments for underserved populations.
PRVs are transferable and highly valuable, with recent sales often exceeding $100 million!
$APLI $APLIF
appilitherapeutics.com/pipeline/
PRVs are transferable and highly valuable, with recent sales often exceeding $100 million!
$APLI $APLIF
appilitherapeutics.com/pipeline/
Pipeline - Appili Therapeutics
PIPELINE Overview Diversified Pipeline Driving Near- And Long-Term Value Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of market and clos...
appilitherapeutics.com
November 20, 2025 at 4:42 PM
Millions suffer from NTDs with limited treatment options. The FDA PRV program incentivizes biotechs to develop treatments for underserved populations.
PRVs are transferable and highly valuable, with recent sales often exceeding $100 million!
$APLI $APLIF
appilitherapeutics.com/pipeline/
PRVs are transferable and highly valuable, with recent sales often exceeding $100 million!
$APLI $APLIF
appilitherapeutics.com/pipeline/
@appili.bsky.social reports financial and operational results for Q2 FY2026
- New NIAID funding award of up to US $40M
- Multiple government proposals submitted, totalling up to US $90M
$APLI $APLIF
appilitherapeutics.com/2025/11/13/a...
- New NIAID funding award of up to US $40M
- Multiple government proposals submitted, totalling up to US $90M
$APLI $APLIF
appilitherapeutics.com/2025/11/13/a...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026 - Appili Therapeutics
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the ...
appilitherapeutics.com
November 14, 2025 at 5:44 PM
@appili.bsky.social reports financial and operational results for Q2 FY2026
- New NIAID funding award of up to US $40M
- Multiple government proposals submitted, totalling up to US $90M
$APLI $APLIF
appilitherapeutics.com/2025/11/13/a...
- New NIAID funding award of up to US $40M
- Multiple government proposals submitted, totalling up to US $90M
$APLI $APLIF
appilitherapeutics.com/2025/11/13/a...
CEO, Don Cilla will represent Appili at the 2025 @bardagov.bsky.social Innovation Symposium on Nov 20 in DC!
Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures.
drive.hhs.gov/innovation20...
$APLI $APLIF
#BARDAInnovation #Biotech
Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures.
drive.hhs.gov/innovation20...
$APLI $APLIF
#BARDAInnovation #Biotech
November 12, 2025 at 6:00 PM
CEO, Don Cilla will represent Appili at the 2025 @bardagov.bsky.social Innovation Symposium on Nov 20 in DC!
Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures.
drive.hhs.gov/innovation20...
$APLI $APLIF
#BARDAInnovation #Biotech
Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures.
drive.hhs.gov/innovation20...
$APLI $APLIF
#BARDAInnovation #Biotech
A new WHO report reveals over a billion people are affected by NTDs.
ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities.
$APLI $APLIF
www.who.int/news/item/22...
ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities.
$APLI $APLIF
www.who.int/news/item/22...
Global progress against neglected tropical diseases continues despite challenges, new WHO report finds
The World Health Organization (WHO) today released the Global report on neglected tropical diseases 2025, the third in a series monitoring progress towards the 2030 targets set in the Road map for neg...
www.who.int
November 6, 2025 at 6:32 PM
A new WHO report reveals over a billion people are affected by NTDs.
ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities.
$APLI $APLIF
www.who.int/news/item/22...
ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities.
$APLI $APLIF
www.who.int/news/item/22...
Appili will attend BARDA Innovation Symposium on November 20 in Washington, DC, highlighting our role as a trusted U.S. government partner.
This event convenes a network of government agencies, non dilutive funders, investors and partners.
$APLI $APLIF
appilitherapeutics.com/2025/10/22/a...
This event convenes a network of government agencies, non dilutive funders, investors and partners.
$APLI $APLIF
appilitherapeutics.com/2025/10/22/a...
Appili Therapeutics to Attend BARDA Innovation Symposium 2025 - Appili Therapeutics
Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation Halifax, Nova Scotia – October 22, 2025 – Appili Therapeutics Inc. (TSX: APLI; OTC Pink...
appilitherapeutics.com
October 22, 2025 at 11:41 AM
Appili will attend BARDA Innovation Symposium on November 20 in Washington, DC, highlighting our role as a trusted U.S. government partner.
This event convenes a network of government agencies, non dilutive funders, investors and partners.
$APLI $APLIF
appilitherapeutics.com/2025/10/22/a...
This event convenes a network of government agencies, non dilutive funders, investors and partners.
$APLI $APLIF
appilitherapeutics.com/2025/10/22/a...
ICYMI: Appili & Vitalex secured a US $40M NIAID contract to advance VXV-01, a first-in-class fungal vaccine. With no approved fungal vaccines for humans, VXV-01 aims to fill an urgent unmet need!
#Biotech #Innovation #Appili
$APLI $APLIF
#Biotech #Innovation #Appili
$APLI $APLIF
October 21, 2025 at 6:02 PM
ICYMI: Appili & Vitalex secured a US $40M NIAID contract to advance VXV-01, a first-in-class fungal vaccine. With no approved fungal vaccines for humans, VXV-01 aims to fill an urgent unmet need!
#Biotech #Innovation #Appili
$APLI $APLIF
#Biotech #Innovation #Appili
$APLI $APLIF
Appili has secured a new NIAID contract worth up to US $40M — bringing our total government funding awards to US $74M, with US $97M more in pending applications.
$APLI $APLIF
#biotech #funding #innovation #Appili
appilitherapeutics.com/2025/10/01/a...
$APLI $APLIF
#biotech #funding #innovation #Appili
appilitherapeutics.com/2025/10/01/a...
October 3, 2025 at 2:53 PM
Appili has secured a new NIAID contract worth up to US $40M — bringing our total government funding awards to US $74M, with US $97M more in pending applications.
$APLI $APLIF
#biotech #funding #innovation #Appili
appilitherapeutics.com/2025/10/01/a...
$APLI $APLIF
#biotech #funding #innovation #Appili
appilitherapeutics.com/2025/10/01/a...
Appili announces US$40M NIAID funding award to advance fungal vaccine, VXV-01, in collaboration with Vitalex Biosciences. VXV-01 is designed to address the urgent threat of invasive fungal infections, affecting millions of people each year.
$APLI $APLIF
appilitherapeutics.com/2025/10/01/a...
$APLI $APLIF
appilitherapeutics.com/2025/10/01/a...
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 - Appili Therapeutics
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U....
appilitherapeutics.com
October 1, 2025 at 6:04 PM
Appili announces US$40M NIAID funding award to advance fungal vaccine, VXV-01, in collaboration with Vitalex Biosciences. VXV-01 is designed to address the urgent threat of invasive fungal infections, affecting millions of people each year.
$APLI $APLIF
appilitherapeutics.com/2025/10/01/a...
$APLI $APLIF
appilitherapeutics.com/2025/10/01/a...
#Appili is pleased to report that all matters from our AGSM have been approved.
These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions.
Stay in touch: info@appilitherapeutics.com
$APLI $APLIF
appilitherapeutics.com/2025/09/23/a...
These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions.
Stay in touch: info@appilitherapeutics.com
$APLI $APLIF
appilitherapeutics.com/2025/09/23/a...
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders - Appili Therapeutics
HALIFAX, Nova Scotia - September 23, 2025 - Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious dis...
appilitherapeutics.com
September 23, 2025 at 9:20 PM
#Appili is pleased to report that all matters from our AGSM have been approved.
These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions.
Stay in touch: info@appilitherapeutics.com
$APLI $APLIF
appilitherapeutics.com/2025/09/23/a...
These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions.
Stay in touch: info@appilitherapeutics.com
$APLI $APLIF
appilitherapeutics.com/2025/09/23/a...
Appili submitted seven U.S. government funding proposals totaling US$137M.
MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities.
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities.
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026 - Appili Therapeutics
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strength...
appilitherapeutics.com
August 20, 2025 at 5:30 PM
Appili submitted seven U.S. government funding proposals totaling US$137M.
MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities.
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities.
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
@appili.bsky.social reports financial and operational results for Q1 FY2026.
- Seven U.S. proposals submitted, totalling up to US $137M
- US $3.3M PRMRP funding application to advance ATI-1701 to IND
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
- Seven U.S. proposals submitted, totalling up to US $137M
- US $3.3M PRMRP funding application to advance ATI-1701 to IND
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026 - Appili Therapeutics
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strength...
appilitherapeutics.com
August 15, 2025 at 4:38 PM
@appili.bsky.social reports financial and operational results for Q1 FY2026.
- Seven U.S. proposals submitted, totalling up to US $137M
- US $3.3M PRMRP funding application to advance ATI-1701 to IND
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
- Seven U.S. proposals submitted, totalling up to US $137M
- US $3.3M PRMRP funding application to advance ATI-1701 to IND
$APLI $APLIF
appilitherapeutics.com/2025/08/14/a...
Check out a new publication co-authored Dr. Gelhaus in Vaccine. The new manuscript showcases the preclinical efficacy of ATI 1701, a novel live attenuated tularemia vaccine with strong potential as a biodefense countermeasure.
appilitherapeutics.com/2025/08/06/a...
#infectiousdiseases
appilitherapeutics.com/2025/08/06/a...
#infectiousdiseases
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine - Appili Therapeutics
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, August 6, 2025 – Appili Therapeuti...
appilitherapeutics.com
August 6, 2025 at 3:02 PM
Check out a new publication co-authored Dr. Gelhaus in Vaccine. The new manuscript showcases the preclinical efficacy of ATI 1701, a novel live attenuated tularemia vaccine with strong potential as a biodefense countermeasure.
appilitherapeutics.com/2025/08/06/a...
#infectiousdiseases
appilitherapeutics.com/2025/08/06/a...
#infectiousdiseases
Last week, Appili CDO, Dr. Nabors joined leaders from government and biodefense at the CWMD & MCDC Membership Meeting.
The MCDC plays a critical role in fostering public–private partnerships to accelerate the development of safe medical countermeasures.
$APLI $APLIF
appilitherapeutics.com/about/
The MCDC plays a critical role in fostering public–private partnerships to accelerate the development of safe medical countermeasures.
$APLI $APLIF
appilitherapeutics.com/about/
About us - Appili Therapeutics
ABOUT US Overview ABOUT US Matching Novel Drug Development Programs With Clearly Defined Patient Needs in Infectious Disease Appili Therapeutics Inc., was founded in 2015 by a team of drug development...
appilitherapeutics.com
July 29, 2025 at 4:33 PM
Last week, Appili CDO, Dr. Nabors joined leaders from government and biodefense at the CWMD & MCDC Membership Meeting.
The MCDC plays a critical role in fostering public–private partnerships to accelerate the development of safe medical countermeasures.
$APLI $APLIF
appilitherapeutics.com/about/
The MCDC plays a critical role in fostering public–private partnerships to accelerate the development of safe medical countermeasures.
$APLI $APLIF
appilitherapeutics.com/about/
@appili.bsky.social reports financial and operational results for FY2025
- Five US government proposals submitted, totalling up to US$125M
- LIKMEZ (ATI-1501) re-launched and commercial sales ongoing
- FDA alignment on ATI-1801 development plans
$APLI $APLIF
appilitherapeutics.com/2025/06/25/a...
- Five US government proposals submitted, totalling up to US$125M
- LIKMEZ (ATI-1501) re-launched and commercial sales ongoing
- FDA alignment on ATI-1801 development plans
$APLI $APLIF
appilitherapeutics.com/2025/06/25/a...
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results - Appili Therapeutics
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, J...
appilitherapeutics.com
June 25, 2025 at 10:16 PM
@appili.bsky.social reports financial and operational results for FY2025
- Five US government proposals submitted, totalling up to US$125M
- LIKMEZ (ATI-1501) re-launched and commercial sales ongoing
- FDA alignment on ATI-1801 development plans
$APLI $APLIF
appilitherapeutics.com/2025/06/25/a...
- Five US government proposals submitted, totalling up to US$125M
- LIKMEZ (ATI-1501) re-launched and commercial sales ongoing
- FDA alignment on ATI-1801 development plans
$APLI $APLIF
appilitherapeutics.com/2025/06/25/a...
Check out the latest publication from Dr. Gelhaus, Ph.D., and US researchers.
“Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic"
$APLI $APLIF
appilitherapeutics.com/2025/05/01/a...
“Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic"
$APLI $APLIF
appilitherapeutics.com/2025/05/01/a...
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia - Appili Therapeutics
A review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks HALIFAX, Nova Scotia, May 1, 2025 – Appili Therapeutics Inc. (TSX:APL...
appilitherapeutics.com
June 12, 2025 at 2:07 PM
Check out the latest publication from Dr. Gelhaus, Ph.D., and US researchers.
“Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic"
$APLI $APLIF
appilitherapeutics.com/2025/05/01/a...
“Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic"
$APLI $APLIF
appilitherapeutics.com/2025/05/01/a...
@who.int Member States have finalized a draft #PandemicAccord to make the world safer from future pandemics.
At @appili.bsky.social, we support these WHO recommendations. To prevent the next pandemic, investments in preparedness measures need to happen today.
$APLI $APLIF
At @appili.bsky.social, we support these WHO recommendations. To prevent the next pandemic, investments in preparedness measures need to happen today.
$APLI $APLIF
Proposals within the text include:
✅ Boosting global collaboration on prevention & preparedness
✅ Strengthening health systems & R&D worldwide
✅ Creating a fair system for pathogen access & benefit-sharing
✅ Building a skilled global health emergency workforce
bit.ly/3EaZQmL
✅ Boosting global collaboration on prevention & preparedness
✅ Strengthening health systems & R&D worldwide
✅ Creating a fair system for pathogen access & benefit-sharing
✅ Building a skilled global health emergency workforce
bit.ly/3EaZQmL
May 14, 2025 at 4:58 PM
@who.int Member States have finalized a draft #PandemicAccord to make the world safer from future pandemics.
At @appili.bsky.social, we support these WHO recommendations. To prevent the next pandemic, investments in preparedness measures need to happen today.
$APLI $APLIF
At @appili.bsky.social, we support these WHO recommendations. To prevent the next pandemic, investments in preparedness measures need to happen today.
$APLI $APLIF
Appili has secured new U.S. & Mexican patents for LIKMEZ, boosting protection for our commercial stage asset until 2039! Now listed in the @fda.gov Orange Book.
$APLI $APLIF
appilitherapeutics.com/2025/04/28/a...
$APLI $APLIF
appilitherapeutics.com/2025/04/28/a...
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™ - Appili Therapeutics
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Fo...
appilitherapeutics.com
April 30, 2025 at 6:38 PM
Appili has secured new U.S. & Mexican patents for LIKMEZ, boosting protection for our commercial stage asset until 2039! Now listed in the @fda.gov Orange Book.
$APLI $APLIF
appilitherapeutics.com/2025/04/28/a...
$APLI $APLIF
appilitherapeutics.com/2025/04/28/a...
This week marks #WorldImmunizationWeek.
#Appili is proud to support the World Immunization Week goal, for more children, adults and communities to be protected from vaccine-preventable diseases, allowing them to live happier, healthier lives
$APLI $APLIF
#Appili is proud to support the World Immunization Week goal, for more children, adults and communities to be protected from vaccine-preventable diseases, allowing them to live happier, healthier lives
$APLI $APLIF
It’s #WorldImmunizationWeek
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
April 24, 2025 at 6:14 PM
This week marks #WorldImmunizationWeek.
#Appili is proud to support the World Immunization Week goal, for more children, adults and communities to be protected from vaccine-preventable diseases, allowing them to live happier, healthier lives
$APLI $APLIF
#Appili is proud to support the World Immunization Week goal, for more children, adults and communities to be protected from vaccine-preventable diseases, allowing them to live happier, healthier lives
$APLI $APLIF
Reposted by Appili Therapeutics
It’s #WorldImmunizationWeek
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
April 24, 2025 at 5:50 AM
It’s #WorldImmunizationWeek
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute.
A reminder of what is #HumanlyPossible. Science saves lives.
#VaccinesWork
bit.ly/wiw2025
“Collaboration across the globe is essential for tackling today’s urgent infectious disease challenges”
At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701.
appilitherapeutics.com/contact/
$APLI $APLIF
At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701.
appilitherapeutics.com/contact/
$APLI $APLIF
April 23, 2025 at 12:38 PM
“Collaboration across the globe is essential for tackling today’s urgent infectious disease challenges”
At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701.
appilitherapeutics.com/contact/
$APLI $APLIF
At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701.
appilitherapeutics.com/contact/
$APLI $APLIF
ICYMI, Appili CEO, Don Cilla joined Aditxt CEO, Amro Albanna at Friday's Weekly Update.
The event highlighted the escalating threat of infectious diseases and emphasized the vital role partnerships play in addressing these challenges.
$APLI $APLIF $ADTX
www.youtube.com/watch?v=S6jf...
The event highlighted the escalating threat of infectious diseases and emphasized the vital role partnerships play in addressing these challenges.
$APLI $APLIF $ADTX
www.youtube.com/watch?v=S6jf...
Appili President and CEO, Don Cilla Joined Aditxt CEO, Amro Albanna Aditxt Weekly Update on 4/4/2025
YouTube video by Aditxt, Inc.
www.youtube.com
April 10, 2025 at 5:05 PM
ICYMI, Appili CEO, Don Cilla joined Aditxt CEO, Amro Albanna at Friday's Weekly Update.
The event highlighted the escalating threat of infectious diseases and emphasized the vital role partnerships play in addressing these challenges.
$APLI $APLIF $ADTX
www.youtube.com/watch?v=S6jf...
The event highlighted the escalating threat of infectious diseases and emphasized the vital role partnerships play in addressing these challenges.
$APLI $APLIF $ADTX
www.youtube.com/watch?v=S6jf...
On Friday at 11:30AM, @appili.bsky.social CEO, Dr. Don Cilla joins Aditxt CEO, Amro Albanna in a Weekly Update, to discuss the transaction status & recent highlights, including $117M in funding applications to advance infectious disease treatments.
us06web.zoom.us/webinar/regi...
$APLI $APLIF $ADTX
us06web.zoom.us/webinar/regi...
$APLI $APLIF $ADTX
April 3, 2025 at 4:01 PM
On Friday at 11:30AM, @appili.bsky.social CEO, Dr. Don Cilla joins Aditxt CEO, Amro Albanna in a Weekly Update, to discuss the transaction status & recent highlights, including $117M in funding applications to advance infectious disease treatments.
us06web.zoom.us/webinar/regi...
$APLI $APLIF $ADTX
us06web.zoom.us/webinar/regi...
$APLI $APLIF $ADTX
Appili’s leadership team will join over 3000 attendees at The World Vaccine Congress in D.C.!
This year, we look forward to gathering with industry leaders, and share recent developments including ATI-1701, our biodefense vaccine candidate.
$APLI $APLIF #WVCUSA #WVC2025 #WVCDC
This year, we look forward to gathering with industry leaders, and share recent developments including ATI-1701, our biodefense vaccine candidate.
$APLI $APLIF #WVCUSA #WVC2025 #WVCDC
March 27, 2025 at 5:31 PM
Last week, Lab Manager, Brandon Green represented Appili at @umkc.bsky.social’s NextGen PATHWAYS Symposium and presented research on ATI-1701.
Appili is proud of our incredible team at the UMKC lab, and excited about progress being made in infectious disease research.
$APLI $APLIF
Appili is proud of our incredible team at the UMKC lab, and excited about progress being made in infectious disease research.
$APLI $APLIF
March 25, 2025 at 5:21 PM
Last week, Lab Manager, Brandon Green represented Appili at @umkc.bsky.social’s NextGen PATHWAYS Symposium and presented research on ATI-1701.
Appili is proud of our incredible team at the UMKC lab, and excited about progress being made in infectious disease research.
$APLI $APLIF
Appili is proud of our incredible team at the UMKC lab, and excited about progress being made in infectious disease research.
$APLI $APLIF
This week at Appili, we’re excited to share four new federal funding proposals have been submitted, totaling US$117M.
During challenging times, Appili remains committed developing critical treatments aligned with public health priorities.
$APLI $APLIF
appilitherapeutics.com/2025/03/18/a...
During challenging times, Appili remains committed developing critical treatments aligned with public health priorities.
$APLI $APLIF
appilitherapeutics.com/2025/03/18/a...
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update - Appili Therapeutics
Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction...
appilitherapeutics.com
March 20, 2025 at 7:06 PM
This week at Appili, we’re excited to share four new federal funding proposals have been submitted, totaling US$117M.
During challenging times, Appili remains committed developing critical treatments aligned with public health priorities.
$APLI $APLIF
appilitherapeutics.com/2025/03/18/a...
During challenging times, Appili remains committed developing critical treatments aligned with public health priorities.
$APLI $APLIF
appilitherapeutics.com/2025/03/18/a...